Viridian Therapeutics Inc. logo

Viridian Therapeutics Inc.

VRDN | NASDAQ
Chart Builder DCF Calculator
$21.60
-$0.40 (-1.82%)
At close: Sep 21, 2026, 4:00 PM ET
$21.58
-$0.02 (-0.09%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$2.44B
Enterprise Value
$1.71B
Beta
0.96
Average Volume
2.22M
Shares Outstanding (Diluted)
107.88M
Shares Change YoY
32.22%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US92790C1045

Price Performance

Price Change 1M
-11.3%
Price Change 3M
25.0%
Price Change 6M
-23.8%
Price Change YTD
-29.6%
Price Change 1Y
10.5%
Price Change 3Y
39.0%
Price Change 5Y
35.3%
1M CAGR (ann.)
-8.5%
1Y CAGR (ann.)
10.0%
5Y CAGR (ann.)
11.7%
All-Time CAGR
-31.0%

Valuation

PE Ratio
-6.12
Forward PE
N/A
PEG Ratio
-0.68
Forward PEG
0.18
PS Ratio
34.40
Forward PS
10.60
PB Ratio
3.70
P/FCF Ratio
-5.38
P/Adj. FCF Ratio
-4.69
P/OCF Ratio
-6.99
EV/Sales
24.01
EV/EBIT
-4.64
EV/EBITDA
-4.64
EV/FCF
-3.76
Earnings Yield
-16.3%
FCF Yield
-18.6%
Adj. FCF Yield
-21.3%

Financial Health

Net Cash
$739.37M
Total Debt
$242.16M
Cash & Short-Term Investments
$981.53M
Total Assets
$1.1B
Current Ratio
16.95
Quick Ratio
16.95
Debt / Equity Ratio
0.37
Debt / EBITDA
-0.66
Debt / FCF
-0.53
OCF / Debt
-1.87
Interest Coverage
-21.40
Altman Z-Score
1.44
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
99.5%
Operating Profit Margin
-569.7%
EBITDA Margin
-517.4%
Net Profit Margin
-544.1%
FCF Margin
-639.3%
Adj. FCF Margin
-733.5%
SBC / Revenue
75.4%
SBC Impact (per share)
-14.7%

Returns

Return on Assets
-35.3%
Return on Equity
-61.4%
Return on Invested Capital
-39.2%
Return on Capital Employed
-39.2%
Return on Tangible Assets
-35.6%

Historical Growth (CAGR)

Revenue CAGR 3Y
264.4%
Revenue CAGR 5Y
93.9%
Revenue CAGR 10Y
37.9%
EPS CAGR 3Y
9.1%
EPS CAGR 5Y
12.1%
EPS CAGR 10Y
18.9%
FCF CAGR 3Y
-46.0%
FCF CAGR 5Y
-39.5%
FCF CAGR 10Y
-32.3%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
16
EPS Growth Next 3Y
45.9%
Revenue Growth Next 3Y
130.8%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
-$0.99
EPS Growth Est (next Q)
190.8%
Revenue Est (next Q)
$4.03M
Revenue Growth Est (next Q)
-94.3%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$36.14
Price Target Upside
67.3%

Cash Flow

Operating Cash Flow
$-453M
Free Cash Flow
$-454.72M
Adj. Free Cash Flow
$-521.72M
FCF Per Share
-$3.11
OCF Per Share
-$3.09
OCF/S Ratio
-468.7%

Income Statement

Revenue
$71.13M
Gross Profit
$70.69M
Operating Income
$-405.2M
EBITDA
$-368.03M
Net Income
$-386.97M
EPS (Diluted)
-$3.53
Revenue / Employee
$282.25K
Profit / Employee
$-1.54M
Employees
252

© 2026 bestshares.com. All rights reserved.